Psychosis: Atypical limbic epilepsy versus limbic hyperexcitability with onset at puberty?

Epilepsy and Behavior

Volumn 10, Issue 4, 2007, Pages 515-520

  Sharp, Frank R ^a   Hendren, Robert L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticonvulsants; Epilepsy; Ketamine; NMDA antagonists; PCP; Phencyclidine; Psychosis

Indexed keywords

ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; DIAZEPAM; DIZOCILPINE; HALOPERIDOL; KETAMINE; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; PHENOBARBITAL; PSYCHEDELIC AGENT;

BIPOLAR DISORDER; BRAIN BLOOD FLOW; BRAIN DEPTH STIMULATION; BRAIN INJURY; BRAIN METABOLISM; CELL DAMAGE; CINGULATE GYRUS; DRUG MEGADOSE; EPILEPSY; GABAERGIC SYSTEM; HUMAN; LIMBIC CORTEX; NEGATIVE SYNDROME; NONHUMAN; POSITIVE SYNDROME; PSYCHOSIS; PUBERTY; REVIEW; SCHIZOPHRENIA; THALAMOCORTICAL TRACT;

ADOLESCENT; ANIMALS; ANTIPSYCHOTIC AGENTS; DIZOCILPINE MALEATE; EPILEPSY; EXCITATORY AMINO ACID ANTAGONISTS; HALLUCINOGENS; HUMANS; KETAMINE; LIMBIC SYSTEM; NEURONS; PHENCYCLIDINE; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; PUBERTY; RATS; REGIONAL BLOOD FLOW; SEXUAL MATURATION;

EID: 34248631694     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2007.02.014     Document Type: Review

References (42)

1. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia [see comments]. Am J Psychiatry 148 (1991) 1301-1308
2. Abi-Saab W.M., D'Souza D.C., Moghaddam B., and Krystal J.H. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 31 Suppl. 2 (1998) 104-109
3. Breier A., Malhotra A.K., Pinals D.A., Weisenfeld N.I., and Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154 (1997) 805-811
4. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
5. Krystal J.H., D'Souza D.C., Petrakis I.L., et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 7 (1999) 125-143
6. Malhotra A.K., Pinals D.A., Weingartner H., et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14 (1996) 301-307
7. Oranje B., van Berckel B.N., Kemner C., van Ree J.M., Kahn R.S., and Verbaten M.N. The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 22 (2000) 293-302
8. 11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34 (2000) 35-43
9. Klafta J.M., Zacny J.P., and Young C.J. Neurological and psychiatric adverse effects of anaesthetics: epidemiology and treatment. Drug Saf 13 (1995) 281-295
10. Lahti A.C., Holcomb H.H., Medoff D.R., and Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport 6 (1995) 869-872
11. Hammer Jr. R.P., and Herkenham M. Altered metabolic activity in the cerebral cortex of rats exposed to ketamine. J Comp Neurol 220 (1983) 396-404
12. Tamminga C. Glutamatergic aspects of schizophrenia. Br J Psychiatry Suppl (1999) 12-15
13. 18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7 (1997) 9-24
14. Duncan G.E., Miyamoto S., and Lieberman J.A. Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation. J Pharmacol Exp Ther 305 (2003) 999-1005
15. Swinkels W.A., Kuyk J., van Dyck R., and Spinhoven P. Psychiatric comorbidity in epilepsy. Epilepsy Behav 7 (2005) 37-50
16. Schmitz B. Depression and mania in patients with epilepsy. Epilepsia 46 Suppl. 4 (2005) 45-49
17. Tugendhaft P., Ansseau M., de Borchgrave V., et al. Guidelines for recognition and treatment of the psychoses associated with epilepsy. Acta Neurol Belg 105 (2005) 14-17
18. Kanner A.M. Recognition of the various expressions of anxiety, psychosis, and aggression in epilepsy. Epilepsia 45 Suppl. 2 (2004) 22-27
19. Kanner A.M. Psychosis of epilepsy: a neurologist's perspective. Epilepsy Behav 1 (2000) 219-227
20. Tamminga C.A. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12 (1998) 21-36
21. Farber N.B., Wozniak D.F., Price M.T., et al. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?. Biol Psychiatry 38 (1995) 788-796
22. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., and Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science 254 (1991) 1515-1518
23. Tomitaka S., Tomitaka M., Tolliver B.K., and Sharp F.R. Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex. Eur J Neurosci 12 (2000) 1420-1430
24. Sharp F.R., Tomitaka M., Bernaudin M., and Tomitaka S. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?. Trends Neurosci 24 (2001) 330-334
25. Feinberg I., Campbell I.G., and Marrs J.C. Intraperitoneal dizocilpine induces cortical spike-wave seizure discharges in rats. Neurosci Lett 196 (1995) 157-160
26. Kohl B.K., and Dannhardt G. The NMDA receptor complex: a promising target for novel antiepileptic strategies. Curr Med Chem 8 (2001) 1275-1289
27. Catarzi D., Colotta V., and Varano F. Competitive AMPA receptor antagonists. Med Res Rev 27 (2007) 239-278
28. Faingold C.L. Emergent properties of CNS neuronal networks as targets for pharmacology: application to anticonvulsant drug action. Prog Neurobiol 72 (2004) 55-85
29. Olney J.W., Labruyere J., and Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs [see comments]. Science 244 (1989) 1360-1362
30. Sharp F.R., Jasper P., Hall J., Noble L., and Sagar S.M. MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Ann Neurol 30 (1991) 801-809
31. Sharp F.R., Butman M., Koistinaho J., et al. Phencyclidine induction of the hsp 70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels. Neuroscience 62 (1994) 1079-1092
32. Nakki R., Nickolenko J., Chang J., Sagar S.M., and Sharp F.R. Haloperidol prevents ketamine- and phencyclidine-induced HSP70 protein expression but not microglial activation. Exp Neurol 137 (1996) 234-241
33. Auer R.N. Effect of age and sex on N-methyl-d-aspartate antagonist-induced neuronal necrosis in rats. Stroke 27 (1996) 743-746
34. Dickerson J., and Sharp F.R. Atypical antipsychotics and a Src kinase inhibitor (PP1) prevent cortical injury produced by the psychomimetic, noncompetitive NMDA receptor antagonist MK-801. Neuropsychopharmacology 31 (2006) 1420-1430
35. Carter K., Dickerson J., Schoepp D.D., et al. The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis. Neuropharmacology 47 (2004) 1135-1145
36. Sharp F.R., Butman M., Wang S., et al. Haloperidol prevents induction of the hsp70 heat shock gene in neurons injured by phencyclidine (PCP), MK801, and ketamine. J Neurosci Res 33 (1992) 605-616
37. Sharp F.R., Butman M., Aardalen K., et al. Neuronal injury produced by NMDA antagonists can be detected using heat shock proteins and can be blocked with antipsychotics. Psychopharmacol Bull 30 (1994) 555-560
38. Farber N.B., Foster J., Duhan N.L., and Olney J.W. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr Res 21 (1996) 33-37
39. Olney J.W., and Farber N.B. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J Clin Psychiatry 55 Suppl. B (1994) 43-46
40. Farber N.B., Kim S.H., Dikranian K., Jiang X.P., and Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 7 (2002) 32-43
41. Brown E.B., McElroy S.L., Keck Jr. P.E., et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 67 (2006) 1025-1033
42. Bowden C.L., and Karren N.U. Anticonvulsants in bipolar disorder. Aust NZ J Psychiatry 40 (2006) 386-393